AEON Biopharma, Inc.

AEON Biopharma, Inc. (CIK 0001837607) is a clinical-stage biopharmaceutical company focused on developing botulinum toxin-based therapeutics for neurological and psychiatric conditions. The company filed a 10-Q with the SEC on May 12, 2022, ahead of its planned business combination with Priveterra Acquisition Corp (Nasdaq: PAQC), the blank-check vehicle sponsored by Priveterra LLC. The de-SPAC transaction, targeting the healthcare and biopharma sector, placed AEON among a cohort of life-sciences companies pursuing public market access through SPAC mergers during that period. For full filing history, sponsor details, deal terms, and real-time status updates on AEON Biopharma and thousands of other SPAC transactions, sign up for a SpacDesk account at spacdesk.com.